Fig. 8: MFHR13 regulates overall AP activation and protects host-like surfaces.
From: A synthetic protein as efficient multitarget regulator against complement over-activation
a Regulation of AP activation. AP in normal human serum was activated in LPS coated wells. The inhibition achieved by addition of regulators was evaluated indirectly by quantifying C5b-9 complex formation by an ELISA-based method. AP activity was set to 100% for wells without regulators and wells with heat-inactivated serum were used as blank. Spontaneous activation was 42 ± 2.8%, measured in wells without LPS. Data represent mean values ± SD from 4 independent measurements. MFHR13 regulatory activity was significantly better than hFH (P < 0.0001, F(DFn, DFd) = 268.5 (1, 34)), and eculizumab (P < 0.0001, F(DFn, DFd) = 83.38 (1, 25)). b Increasing concentrations of MFHR13 protected sheep erythrocytes from human complement attack in FH-depleted serum significantly better than MFHR1I62 (P = 0.0003, F(DFn, Dfd) = 16.02 (1, 36)), MFHR1V62 (P < 0.0001, F(DFn, Dfd) = 54.99 (1, 42)), hFH (P = 0.0001, F(DFn, DFd)) = 18.73 (1, 31)), and eculizumab (P < 0.0001 F(DFn, DFd)) = 111.7 (1, 33)). Hemolysis was set to 100% for wells without complement regulators and the negative control without FH-depleted serum was used as blank. Data represent mean values ± SD from 4 independent measurements. Δxt/ft is a purified extract from the parental moss line used as negative control. DF degrees of freedom.
